JP2025503971A5 - - Google Patents

Info

Publication number
JP2025503971A5
JP2025503971A5 JP2024544447A JP2024544447A JP2025503971A5 JP 2025503971 A5 JP2025503971 A5 JP 2025503971A5 JP 2024544447 A JP2024544447 A JP 2024544447A JP 2024544447 A JP2024544447 A JP 2024544447A JP 2025503971 A5 JP2025503971 A5 JP 2025503971A5
Authority
JP
Japan
Prior art keywords
cancer
pharmaceutical composition
pharmaceutically acceptable
mta
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024544447A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025503971A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/011658 external-priority patent/WO2023146989A1/en
Publication of JP2025503971A publication Critical patent/JP2025503971A/ja
Publication of JP2025503971A5 publication Critical patent/JP2025503971A5/ja
Pending legal-status Critical Current

Links

JP2024544447A 2022-01-26 2023-01-26 化合物及び使用方法 Pending JP2025503971A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263303497P 2022-01-26 2022-01-26
US63/303,497 2022-01-26
PCT/US2023/011658 WO2023146989A1 (en) 2022-01-26 2023-01-26 Compounds and methods of use

Publications (2)

Publication Number Publication Date
JP2025503971A JP2025503971A (ja) 2025-02-06
JP2025503971A5 true JP2025503971A5 (cg-RX-API-DMAC7.html) 2026-02-16

Family

ID=85382515

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024544447A Pending JP2025503971A (ja) 2022-01-26 2023-01-26 化合物及び使用方法

Country Status (4)

Country Link
US (1) US20250171432A1 (cg-RX-API-DMAC7.html)
EP (1) EP4469447A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025503971A (cg-RX-API-DMAC7.html)
WO (1) WO2023146989A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025504916A (ja) * 2022-01-26 2025-02-19 タンゴ セラピューティクス, インコーポレイテッド 化合物及び使用方法
CN117658980A (zh) * 2022-09-08 2024-03-08 郑州同源康医药有限公司 双环类prmt5抑制剂
CN118359607A (zh) * 2023-01-17 2024-07-19 苏州浦合医药科技有限公司 Prmt5-mta抑制剂
WO2024213044A1 (en) * 2023-04-14 2024-10-17 Beijing Double-Crane Runchuang Technology Co., Ltd. Azacyclo-carbonyl-fused ring derivatives and use thereof
PE20260121A1 (es) 2023-04-21 2026-01-16 Gilead Sciences Inc Inhibidores de prmt5 y usos de los mismos
WO2025217297A1 (en) 2024-04-09 2025-10-16 Tango Therapeutics, Inc. Prmt5 inhibitors for use in methods of treating mta-accumulating cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
WO2011079236A1 (en) 2009-12-22 2011-06-30 The Ohio State University Research Foundation Compositions and methods for cancer detection and treatment
CN116568677B (zh) * 2020-07-31 2026-07-28 探戈医药股份有限公司 可用于治疗mtap缺乏和/或mta累积癌症的哌啶-1-基-n-吡啶-3-基-2-氧代乙酰胺衍生物
IL308853A (en) * 2021-06-02 2024-01-01 Ideaya Biosciences Inc Combination therapy comprising a mat2a inhibitor and a type ii prmt inhibitor
CN117658980A (zh) * 2022-09-08 2024-03-08 郑州同源康医药有限公司 双环类prmt5抑制剂

Similar Documents

Publication Publication Date Title
JP7190549B2 (ja) Hdac阻害剤とpd-1阻害剤との組み合わせ療法
JP7190548B2 (ja) Hdac阻害剤とpd-l1阻害剤との組み合わせ療法
Li et al. HER2-mediated internalization of cytotoxic agents in ERBB2 amplified or mutant lung cancers
Barroso-Sousa et al. Clinical Development of New Antibody–Drug Conjugates in Breast Cancer: To Infinity and Beyond: R. Barroso-Sousa et al.
RU2020114632A (ru) Терапевтические способы, относящиеся к ингибиторам hsp90
Jimeno et al. A randomized, phase 2 trial of docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer
Gainor et al. Alectinib dose escalation reinduces central nervous system responses in patients with anaplastic lymphoma kinase–positive non–small cell lung cancer relapsing on standard dose alectinib
Singh et al. Single agent and synergistic activity of the “first-in-class” dual PI3K/BRD4 inhibitor SF1126 with sorafenib in hepatocellular carcinoma
US20120130144A1 (en) Treatment of lung cancer with a nitrobenzamide compound in combination with a growth factor inhibitor
JP2019501204A5 (cg-RX-API-DMAC7.html)
WO2021183318A2 (en) Methods and compositions relating to improved combination therapies
JP2018508469A5 (cg-RX-API-DMAC7.html)
JP2019507721A5 (cg-RX-API-DMAC7.html)
JP2020535173A5 (cg-RX-API-DMAC7.html)
JP2020505433A5 (cg-RX-API-DMAC7.html)
WO2020078905A1 (en) Combination therapy utilizing dna alkylating agents and atr inhibitors
WO2022031952A9 (en) Treatments for cancers having kras mutations
TW202537643A (zh) 抗體-藥物結合物之用途
JP2016530273A (ja) 癌を治療するためのhdac8阻害剤
RU2017146346A (ru) Комбинированная терапия pac-1
JP2025540925A (ja) 癌の治療におけるアゼノセルチブの断続的投与レジメン
JP2021519302A5 (cg-RX-API-DMAC7.html)
EP3793564A1 (en) Compositions comprising bisfluoroalkyl-l,4-benzodiazepinone compounds for treating adenoid cystic carcinoma
JP2018537519A5 (cg-RX-API-DMAC7.html)
Chakraborty et al. AZD4625 is a potent and selective inhibitor of KRASG12C